DK1290023T3 - Nuklearfaktor KB inducerende faktor - Google Patents

Nuklearfaktor KB inducerende faktor

Info

Publication number
DK1290023T3
DK1290023T3 DK01920925.3T DK01920925T DK1290023T3 DK 1290023 T3 DK1290023 T3 DK 1290023T3 DK 01920925 T DK01920925 T DK 01920925T DK 1290023 T3 DK1290023 T3 DK 1290023T3
Authority
DK
Denmark
Prior art keywords
nfif
polypeptides
methods
factor
nfkb
Prior art date
Application number
DK01920925.3T
Other languages
Danish (da)
English (en)
Inventor
June Kaplow
Thomas Haws
Marie Rosier
Patrice Denefle
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0018307.9A external-priority patent/GB0018307D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1290023T3 publication Critical patent/DK1290023T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01920925.3T 2000-03-31 2001-04-02 Nuklearfaktor KB inducerende faktor DK1290023T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19390500P 2000-03-31 2000-03-31
GBGB0018307.9A GB0018307D0 (en) 2000-07-26 2000-07-26 Polypeptides
PCT/US2001/010719 WO2001074900A2 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor

Publications (1)

Publication Number Publication Date
DK1290023T3 true DK1290023T3 (da) 2011-02-14

Family

ID=26244722

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01920925.3T DK1290023T3 (da) 2000-03-31 2001-04-02 Nuklearfaktor KB inducerende faktor

Country Status (14)

Country Link
EP (1) EP1290023B1 (enExample)
JP (1) JP4750999B2 (enExample)
KR (1) KR100811571B1 (enExample)
AT (1) ATE486089T1 (enExample)
AU (1) AU4793101A (enExample)
CA (1) CA2404688C (enExample)
DE (1) DE60143354D1 (enExample)
DK (1) DK1290023T3 (enExample)
IL (3) IL151987A0 (enExample)
MX (1) MXPA02009481A (enExample)
NO (1) NO331972B1 (enExample)
NZ (1) NZ521786A (enExample)
PT (1) PT1290023E (enExample)
WO (1) WO2001074900A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486053T3 (de) 1983-10-20 2004-01-08 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
WO1997037020A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6132964A (en) * 1998-02-06 2000-10-17 Incyte Pharmaceuticals, Inc. Hydrolase enzymes
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6077672A (en) * 1998-08-28 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of TRADD expression
CN1302897A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1358347A2 (en) * 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
EP1358349A2 (en) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
IL151987A (en) 2010-12-30
AU4793101A (en) 2001-10-15
HK1053312A1 (en) 2003-10-17
EP1290023A2 (en) 2003-03-12
KR100811571B1 (ko) 2008-03-10
IL151987A0 (en) 2003-04-10
NO331972B1 (no) 2012-05-14
JP2003529360A (ja) 2003-10-07
KR20020087459A (ko) 2002-11-22
WO2001074900A9 (en) 2003-03-06
CA2404688C (en) 2012-07-31
CA2404688A1 (en) 2001-10-11
JP4750999B2 (ja) 2011-08-17
WO2001074900A3 (en) 2002-05-02
WO2001074900A2 (en) 2001-10-11
PT1290023E (pt) 2011-01-05
NO20024656D0 (no) 2002-09-27
IL198132A0 (en) 2011-08-01
EP1290023B1 (en) 2010-10-27
MXPA02009481A (es) 2004-05-14
NZ521786A (en) 2004-07-30
NO20024656L (no) 2002-11-28
DE60143354D1 (de) 2010-12-09
ATE486089T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
CY1120241T1 (el) Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
NO20033862D0 (no) Fremgangsmåter for forebyggelse eller behandling av inflammatoriske eller autoimmune sykdommer ved administrering av integrin-alfa-beta3-antagonister
ATE232396T1 (de) Oxydiertes thymosin beta 4
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
FR2849781B1 (fr) Sonde de therapie
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DE60236010D1 (de) Kalibrierung der gewebedichte in der computertomographie
NO985822L (no) System for Õ mÕle og analysere HLR parametere for anvendelse med og av en ekstern defibrillator
DE60221569D1 (de) Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen
ITMI20010684A0 (it) Dispositivo e procedimento di controllo della entita' del grasso intra-addominale
ATE511655T1 (de) Verfahren zur auswertung eines myelounterdrückungszustands
EP1796625A4 (en) NEW FENOFIBRATE FORMULATIONS AND RELEVANT TREATMENT METHODS
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
FR2834889B1 (fr) Forme pharmaceutique solide orodispersible
HUP9900819A1 (hu) Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
ITNA20000036A0 (it) Nuovi approcci terapeutici per il trattamento della forfora.
GB0101124D0 (en) DNA element and assoc
ATE486089T1 (de) Nuklearfaktor kb induzierender faktor
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
ATE406438T1 (de) Menschliches homolog aus der familie der metalloproteasen
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
EP1399179A4 (en) PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROLIFERATION OF HYPOPHYENADENOMES AND METHOD FOR THEIRIR USE
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
BR0109721A (pt) Fator de indução do fator kb nuclear